AP Biosciences Inc

Taipei Exchange 6945.TWO

AP Biosciences Inc EBITDA for the year ending December 31, 2023: USD -10.60 M

AP Biosciences Inc EBITDA is USD -10.60 M for the year ending December 31, 2023, a -12.06% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.
  • AP Biosciences Inc EBITDA for the year ending December 31, 2022 was USD -9.46 M, a -47.48% change year over year.
  • AP Biosciences Inc EBITDA for the year ending December 31, 2021 was USD -6.42 M, a -345,716.28% change year over year.
  • AP Biosciences Inc EBITDA for the year ending December 31, 2020 was USD 1.86 K.
Key data
Date EBITDA Net Income EPS (Diluted) Shares (Diluted, Weighted)
Market news
Taipei Exchange: 6945.TWO

AP Biosciences Inc

CEO Dr. Jeng-Horng Her Ph.D.
IPO Date July 14, 2023
Location
Headquarters No. 508, Zhongxiao East Road
Employees 37
Sector Health Care
Industries
Biotechnology Clinical Trials Pharmaceuticals
Description

AP Biosciences Inc, a clinical-stage biopharmaceutical company, researches and develops bispecific antibody drugs for unmet medical needs. It develops IBI302 that is in phase III clinical trials for the treatment of neovascular age-related macular degeneration; AP505 that is in phase I clinical trials for treating solid tumors; AP203 that is in phase I clinical trial for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous-cell carcinomas; AP402, which is in in the pre-clinical research phase for breast cancer patients; and AP601 that is in pre-clinical research phase for treating lung cancer, pancreatic cancer, bladder cancer, ovarian cancer, and other solid tumors. The company was founded in 2013 and is based in Taipei City, Taiwan.

StockViz Staff

January 15, 2025

Any question? Send us an email